Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | E7046 |
| Trade Name | |
| Synonyms | AN0025|E-7046|E 7046 |
| Drug Descriptions |
AN0025 (E7046) is a small molecule inhibitor of E2 receptor type 4 (EP4), which may result in antitumor activity including inhibition of cell proliferation and reduced tumor growth (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B198, PMID: 32554609). |
| DrugClasses | |
| CAS Registry Number | 1369489-71-3 |
| NCIT ID | C129689 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + Buparlisib + E7046 | Atezolizumab Buparlisib E7046 | 0 | 1 |
| Atezolizumab + E7046 | Atezolizumab E7046 | 0 | 1 |
| Capecitabine + E7046 | Capecitabine E7046 | 0 | 1 |
| Durvalumab + E7046 | Durvalumab E7046 | 0 | 1 |
| E7046 | E7046 | 0 | 1 |
| E7046 + Fluorouracil + Leucovorin + Oxaliplatin | E7046 Fluorouracil Leucovorin Oxaliplatin | 0 | 1 |
| E7046 + Pembrolizumab | E7046 Pembrolizumab | 0 | 1 |
| E7046 + Radiotherapy | E7046 Radiotherapy | 0 | 0 |